MASH Drug Landscape 2026: $8B Mega-Deals & FGF21 Pipeline
2025-2026 MASH update: GSK, Roche, Novo Nordisk $8B+ mega-deals, FGF21 pipelines, Rezdiffra EU launch, Wegovy MASH approval, F4 cirrhosis endpoints.
Introduction
MASH (Metabolic Dysfunction-Associated Steatohepatitis) has emerged as an area of intense pharmaceutical industry focus due to extremely high unmet medical needs. From 2025 through 2026, this space has been transformed by major Big Pharma acquisitions that significantly reshaped the competitive landscape.
This article provides a comprehensive analysis of the MASH development race across 2025-2026 from the perspectives of acquisitions, partnerships, approvals, and the post-deal integration phase.
Quick Answer: 2025-2026 has been the consolidation period for MASH: three Big Pharma mega-deals totaling over $8B reshaped the field — GSK→Boston Pharma ($1.2B), Roche→89bio (up to $3.5B), and Novo Nordisk→Akero ($5.2B). The acquisitions centered on FGF21 analogs (efimosfermin, pegozafermin, efruxifermin), while Rezdiffra's commercial expansion and Wegovy's MASH approval are defining the emerging market. The next strategic axes are F4 compensated-cirrhosis endpoints and GLP-1 / THR-β / FGF21 combination pipelines.
[!TIP] Cross-disease DMT strategy Anti-fibrotic disease-modifying therapies (DMTs) are undergoing a paradigm shift toward a "pan-fibrosis" approach that spans IPF, MASH, CKD, and other indications. For a hub overview of cross-disease pipeline trends, see Anti-Fibrotic Drug Pipeline 2026: Cross-Disease Approaches.
[!TIP] Cross-disease market view To place this MASH M&A wave (GSK / Roche / Novo Nordisk, $8B+ combined) within the broader fibrosis drug market — including IPF and CKD market sizes, deals, and pipeline opportunities — see Fibrosis Drug Market 2026: IPF, MASH, CKD Forecasts.
[!TIP] F4 cirrhosis as the strategic axis ENLIGHTEN-Cirrhosis (pegozafermin F4), the Akero deal milestone tied to compensated cirrhosis approval, and MAESTRO-NASH-OUTCOMES (resmetirom F4) all hinge on the compensated/decompensated cirrhosis boundary and decompensation-prevention endpoints. The clinical definitions (HVPG, MELD 3.0, Child-Pugh, Baveno VII, AASLD 2024) and trial-design implications are detailed in Compensated vs Decompensated Cirrhosis: MASH Endpoint Guide.
【Q1 2026 Landscape Update】Integration Phase and Next Strategic Axes
The three mega-deals concluded in 2025 are advancing into the post-acquisition integration phase as of Q1 2026. With Phase 3 programs underway for the FGF21 analogs pegozafermin and efruxifermin, the three acquiring Big Pharma companies are focused on clinical infrastructure integration, commercial organization buildout, and combination pipeline design.
The competitive frontier is shifting through 2026 along three axes:
- F4 compensated-cirrhosis endpoint: ENLIGHTEN-Cirrhosis (pegozafermin), SYNCHRONY-Outcomes (efruxifermin), and MAESTRO-NASH-OUTCOMES (resmetirom) compete on decompensation-free survival as the long-term outcome metric
- GLP-1 / FGF21 / THR-β combination design: Wegovy (F2-F3 MASH approved) plus Rezdiffra and FGF21 analog combination pipelines are expected to enter Phase 2/3 development from H2 2026
- EU and Asia regulatory expansion: Following Rezdiffra's German launch (September 2025), additional European markets and Japan are next, alongside Wegovy MASH indication reviews by national regulators
For combination pipeline analysis see MASH Combination Therapy Strategies 2026; for market sizing see Fibrosis Drug Market 2026.
For researchers tracking fibrosis & inflammation R&D
FDA approval alerts, trial readouts, preclinical model selection, and assay optimization — curated signal for bench-to-pipeline readers. 2 emails/month max.
MASH: Wave of Big Pharma Mega-Acquisitions
Major Acquisition Deals
The MASH space in 2025 witnessed three major Big Pharma acquisitions.
1. GSK → Boston Pharmaceuticals (May 2025)
In May 2025, GSK agreed to acquire Boston Pharmaceuticals' lead asset, efimosfermin alfa (formerly BOS-580), for an upfront payment of $1.2 billion, with up to $800 million in potential milestone payments; the acquisition completed in July 202512.
Key Asset Characteristics:
- Efimosfermin alfa demonstrated significant improvements in liver fibrosis and MASH resolution in Phase 2 trials involving patients with F2/F3 fibrosis3
- GSK plans to develop the drug for a broader range of steatotic liver diseases (SLD), including MASH and alcohol-related liver disease (ALD), targeting commercialization in 202924
2. Roche → 89bio (September 2025)
In September 2025, Roche entered into a definitive agreement to acquire 89bio for an upfront equity value of approximately $2.4 billion, with an additional CVR component bringing total potential deal value to approximately $3.5 billion; Roche completed the acquisition in October 202556.
Key Asset Characteristics:
- Lead candidate pegozafermin is a fibroblast growth factor 21 (FGF21) analog targeting moderate to severe MASH treatment5. The Phase 2b ENLIVEN trial (F2-F3, 24 weeks, NCT04929483) reported a 26% fibrosis-improvement rate at 30 mg weekly vs 7% placebo8b
- Phase 3 trials ENLIGHTEN-Fibrosis (non-cirrhotic F2-F3 patients) and ENLIGHTEN-Cirrhosis (compensated cirrhotic F4 patients) are ongoing78
- ClinicalTrials.gov records list primary completion estimates in 2029 for ENLIGHTEN-Fibrosis and 2028 for ENLIGHTEN-Cirrhosis78
3. Novo Nordisk → Akero Therapeutics (October 2025)
In October 2025, Novo Nordisk entered into an agreement to acquire Akero Therapeutics for an upfront equity value of approximately $4.7 billion, with up to an additional $500 million contingent upon US regulatory approval for compensated cirrhosis due to MASH; the acquisition completed in December 2025910.
Key Asset Characteristics:
- Lead candidate efruxifermin (EFX) is an FGF21 analog positioned by Akero and Novo Nordisk as a potential best-in-class therapy for MASH911
- Under development in the Phase 3 SYNCHRONY program for both pre-cirrhotic MASH (F2-F3) and compensated cirrhosis (F4)1213
- Phase 2b SYMMETRY trial (F4 compensated cirrhosis): the 36-week primary endpoint was not met; the extended 96-week analysis reported a higher proportion in the 50-mg arm achieving the fibrosis-improvement endpoint (29% [18/63] vs placebo 11% [7/61])1111b. Phase 2b HARMONY (F2-F3, 96 weeks): 50-mg group achieved 49% (21/43) vs placebo 19% (8/43), p=0.003011c
Approved Therapeutics
Madrigal Pharmaceuticals - Rezdiffra (resmetirom)
- US FDA accelerated approval obtained March 14, 20241414b; conditional marketing authorization from the European Commission (EMA EPAR) in August 20251515b. Conversion to US traditional approval pending outcomes confirmation
- First approved drug for non-cirrhotic MASH with F2-F3 fibrosis in the US and EU1414b. Non-invasive biomarkers (FIB-4, ELF test, etc.) played a critical role as surrogate endpoints in approval trials (particularly the ELF score, which received FDA De Novo authorization as a prognostic marker)
- Launched in Germany in September 202516
Novo Nordisk - Wegovy (semaglutide)
- In August 2025, the US FDA granted accelerated approval to Wegovy for adult non-cirrhotic MASH patients with moderate to advanced liver fibrosis1717b
- In December 2025, Health Canada granted conditional marketing authorization for non-cirrhotic MASH (F2-F3 fibrosis)18
Companies Seeking Partners
Viking Therapeutics
- Phase 2b VOYAGE trial of lead candidate VK2809 showed favorable 52-week histological data1920
- As of the latest company materials reviewed for this update, VK2809 remains a company-controlled, late-stage-ready MASH asset rather than an announced Big Pharma acquisition target20
Retreating Companies
Gilead Sciences
- Gilead previously tested cilofexor and firsocostat-containing regimens in advanced NASH/MASH, including the Phase 2 ATLAS study, but the histology endpoint was not met across active arms versus placebo21
- Gilead's current public pipeline page is centered on virology, oncology, and inflammation programs and does not list a named clinical-stage MASH program in the public pipeline table reviewed for this update22
Industry Map: Visualizing Company Relationships
The following Mermaid diagram visualizes the major acquisitions, approvals, and development status in the MASH space in 2025.
Legend:
- 🔵 Blue: Big Pharma (acquiring companies)
- 🟢 Green: Approved companies
- 🔴 Red: Retreating/discontinued companies
- 🟠 Orange: Companies seeking partners
Analysis: Industry Trend Analysis
1. Big Pharma Acquisition of De-Risked Assets
All three major MASH acquisitions in 2025 (GSK/Boston, Roche/89bio, Novo/Akero) involved "de-risked" assets with positive Phase 2 or later data. This demonstrates Big Pharma's strategy of avoiding early-stage development risks and entering the market after some degree of efficacy has been confirmed.
2. Concentration on FGF21 Analogs
Both pegozafermin (89bio) and efruxifermin (Akero), acquired by Roche and Novo Nordisk respectively, are FGF21 analogs. This concentration indicates that the FGF21 pathway is being valued as a differentiated mechanism for anti-fibrotic and anti-inflammatory effects.
3. Indication Expansion and Combination Strategies
GSK's efimosfermin alfa is pursuing indication expansion beyond MASH to alcohol-related liver disease (ALD). Additionally, the possibility of combination therapy with existing anti-fibrotic drugs is being explored, suggesting that combination strategies will become increasingly important in future development.
Conclusion
The MASH space in 2025 experienced accelerated industry consolidation with multiple Big Pharma mega-acquisitions. GSK, Roche, and Novo Nordisk invested over $8 billion collectively to acquire promising biotech assets and secure market entry.
Going forward, all eyes are on Phase 3 readouts and regulatory decisions for these acquired assets. Whether the FGF21 analogs secured by Roche and Novo Nordisk deliver compelling clinical data in 2027 and beyond will largely determine the future trajectory of MASH therapy.
FAQ
Q: Why did Big Pharma cluster so tightly around FGF21 analogs in 2025? A: FGF21 is one of the few targets that simultaneously drives hepatic lipid metabolism, anti-fibrotic effects, and anti-inflammatory activity. Phase 2 data showed significant F2-F3 fibrosis improvement, and its subcutaneous dosing regimen (weekly to bi-weekly) is patient-friendly and combines cleanly with GLP-1 agonists. The main differentiator between pegozafermin (89bio) and efruxifermin (Akero) is PK profile and dosing frequency.
Q: Will Rezdiffra (resmetirom) and the upcoming FGF21 analogs compete directly? A: Short term yes, long term they likely combine. Rezdiffra (THR-β agonist) is strong on hepatic lipid lowering and MASH resolution; FGF21 analogs differentiate on fibrosis reversal and insulin sensitization. With distinct MoAs, "THR-β + FGF21" and "GLP-1 + FGF21" Phase 2/3 combination trials will dominate the 2027+ landscape. See MASH combination therapy strategy 2026.
Q: What does Gilead's MASH exit signal for the industry? A: The cautious interpretation is that Gilead's prior FXR/ACC-centered NASH work did not generate a clear enough histology signal to keep it visible as a major late-stage MASH program. More broadly, once Rezdiffra and Wegovy became approved comparators, later-entrant combination programs face a higher bar for proving incremental benefit.
Q: Why is Viking Therapeutics (VK2809) still seeking a partner rather than being acquired? A: No announced acquisition was identified in the primary company materials reviewed for this update. VK2809 is a THR-β agonist, the same broad class as Rezdiffra, so its strategic value likely depends on whether Phase 3 planning can show a differentiated profile versus an already approved first mover.
Q: Where do Japanese pharma companies stand in MASH development? A: Otsuka (OPC-163493) and a few Kyowa Kirin exploratory programs remain in early stages, but no purely Japan-originated MASH drug has reached global Phase 3. Takeda has already exited antifibrotic strategy. The practical paths for Japanese players today are (a) out-licensing early-stage assets, or (b) acquiring Japan-market rights to overseas Phase 3 candidates.
Moving forward, the Phase 3 results and regulatory approvals of these acquired assets will be closely watched. Particularly, the clinical performance of the FGF21 analogs acquired by Roche and Novo Nordisk from 2027 onwards will significantly shape the future of MASH treatment.
Related Articles
- Comprehensive Guide to MASLD/MASH Biomarkers — The complete picture of non-invasive biomarkers essential for MASH clinical development, including FIB-4, ELF test, and Pro-C3
- Anti-Fibrotic Drug Pipeline 2026: Cross-Disease Approaches — Latest developments in pan-fibrosis therapeutics spanning IPF, MASH, and CKD
- MASH Therapeutics Comprehensive Analysis: Pipeline by Mechanism — Detailed analysis of major MASH drug candidates by MOA, clinical stage, and competitive landscape
- MASH Combination Therapy Strategies 2026 — Frontier of GLP-1 + FGF21, GLP-1 + THR-β, and other combination approaches
- The Future of MASH: Post-2030 Treatment Paradigm Shifts — Next-generation modalities, gene therapy, and prevention strategies
- ALD vs MASLD Models: Alcoholic vs Metabolic Liver Disease — Selection criteria and pathology differences between ALD and MASLD models
- MASH Model Selection Guide: MoA-Based Decision Matrix — Compare GAN, CDA-HFD, CCl4, STAM and more by drug mechanism of action
References
1.GSK: GSK to acquire efimosfermin, a phase III-ready potential best-in-class specialty medicine
2.GSK: GSK completes acquisition of efimosfermin
4.GSK: Efimosfermin receives US FDA Breakthrough Therapy and EMA PRIME designations for MASH
5.Roche: Roche enters into a definitive merger agreement to acquire 89bio
6.Roche: Roche purchases shares in tender offer for 89bio
7.ClinicalTrials.gov: ENLIGHTEN-Fibrosis, pegozafermin in MASH with F2/F3 fibrosis (NCT06318169)
8b. Loomba R, Sanyal AJ, et al. Randomized, Controlled Trial of the FGF21 Analogue Pegozafermin in NASH (ENLIVEN). N Engl J Med. 2023;389(11):998-1008. PubMed PMID 37356033 / ClinicalTrials.gov NCT04929483 / DOI: 10.1056/NEJMoa2304286
9.Akero Therapeutics: Akero to be acquired by Novo Nordisk for up to $5.2 billion
10.Akero Therapeutics / Novo Nordisk: Novo Nordisk completes acquisition of Akero Therapeutics
11.Akero Therapeutics: Week 96 SYMMETRY results for efruxifermin in compensated cirrhosis due to MASH
11b. Noureddin M, Rinella ME, Chalasani NP, et al. Efruxifermin in Compensated Liver Cirrhosis Caused by MASH (SYMMETRY). N Engl J Med. 2025;392(24):2413-2424. PubMed PMID 40341827 / ClinicalTrials.gov NCT05039450 — 36-week primary endpoint not met; extended 96-week analysis.
11c. Noureddin M, Frias JP, Neff GW, et al. Safety and efficacy of once-weekly efruxifermin versus placebo in MASH (HARMONY): 96-week results. Lancet. 2025;406(10504):719-730. PubMed PMID 40818852 / DOI: 10.1016/S0140-6736(25)01073-6
14.FDA: FDA Approves First Treatment for Patients with Liver Scarring Due to Fatty Liver Disease
14b. DailyMed: Rezdiffra (resmetirom) Prescribing Information — current label
15.Madrigal Pharmaceuticals: European Commission approval for Rezdiffra
15b. EMA: Rezdiffra (resmetirom) EPAR — Conditional Marketing Authorisation, 2025-08-18
16.Madrigal Pharmaceuticals: Q3 2025 corporate update including Germany launch
17.FDA: FDA approves Wegovy for serious liver disease known as MASH
19.Viking Therapeutics: Positive 52-week histologic data from Phase 2b VOYAGE study of VK2809
20.Viking Therapeutics: VK2809 pipeline page
21.Gilead: Topline results from Phase 2 ATLAS study in NASH F3/F4